Back to results
US 8,617,831 B2Granted
Methods for diagnosing and monitoring the progression of cancer by measuring soluble c-Met ectodomain
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Amgen Inc.
InventorsDonald P. Bottaro, Gagani P. Athauda, Teresa Lynn Burgess
Life of this patent
Estimating the term…
Abstract
Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.
Claims16
A method of monitoring the status of cancer in a patient comprising:
- determining the concentration of soluble c-Met ectodomain in a first biological tissue from the patient at a first time point,
- determining the concentration of soluble c-Met ectodomain in a second biological tissue from the patient at a second time point that is later than the first time point, wherein the first and second biological tissues are the same type of tissues, and
- determining the status of cancer in the patient by comparing the concentration of soluble c-Met ectodomain in the first and second biological tissues
- wherein a difference in the concentration of soluble c-Met ectodomain in the first and second biological tissues indicates that the patient's cancer has regressed or worsened;
- and
- wherein similar concentrations of soluble c-Met ectodomain in the first and second biological tissues indicates that the patient's cancer has remained stable;
- and
- wherein a lower concentration of soluble c-Met ectodomain in the second biological tissue than that in the first biological tissue indicates that the patient's cancer has regressed;
- and
- wherein a greater concentration of soluble c-Met ectodomain in the second biological tissue than that in the first biological tissue indicates that the patient's cancer has worsened.
7 more elements
A method for measuring a patient's response to cancer therapy comprising:
- determining the concentration of soluble c-Met ectodomain in a biological tissue from the patient at a first time point,
- determining the concentration of soluble c-Met ectodomain in a second biological tissue from the patient at a second time point that is later than the first time point, wherein the first and second biological tissues are the same type of tissues, and
- determining the patient's response to cancer therapy by comparing the concentration of soluble c-Met ectodomain in the first and second biological tissues
- wherein a difference in the concentration of soluble c-Met ectodomain in the first and second biological tissues indicates that the patient's cancer has regressed or worsened;
- and
- wherein similar concentrations of soluble c-Met ectodomain in the first and second biological tissues indicates that the patient has not responded to the cancer therapy;
- and
- wherein a lower concentration of soluble c-Met ectodomain in the second biological tissue relative to that in the first biological tissue indicates that the patient has responded positively to the cancer therapy;
- and
- wherein a greater concentration of soluble c-Met ectodomain in the second biological tissue than that in the first biological tissue indicates that the patient has not responded to the cancer therapy or has responded negatively to the cancer therapy.
7 more elements
Dependencies are inferred from the claim text.